Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome.

Niewinna K, Zielińska A, Fichna J.

Expert Opin Pharmacother. 2019 Nov 14:1-12. doi: 10.1080/14656566.2019.1688784. [Epub ahead of print]

PMID:
31724881
2.

Free Fatty Acid Receptors as new potential target in Colorectal Cancer.

Bartoszek A, Fichna J, Tarasiuk A, Binienda A, Fabisiak A, Krajewska JB, Mosińska P, Niewinna K, Salaga M.

Curr Drug Targets. 2019 Nov 12. doi: 10.2174/1389450120666191112141901. [Epub ahead of print]

PMID:
31721710
3.

Berberine as a potential therapeutic agent in the treatment of acute pancreatitis

Tarasiuk A, Pawlik L, Fichna J.

Postepy Biochem. 2019 Oct 1;65(3):224-230. doi: 10.18388/pb.2019_278. Review. Polish.

PMID:
31643170
4.

Chain length of dietary fatty acids determines gastrointestinal motility and visceromotor function in mice in a fatty acid binding protein 4-dependent manner.

Mosińska P, Szczepaniak A, Wojciechowicz T, Skrzypski M, Nowak K, Fichna J.

Eur J Nutr. 2019 Sep 27. doi: 10.1007/s00394-019-02094-2. [Epub ahead of print]

PMID:
31562532
5.

Gut microbiota: what is its place in pharmacology?

Tarasiuk A, Fichna J.

Expert Rev Clin Pharmacol. 2019 Oct;12(10):921-930. doi: 10.1080/17512433.2019.1670058. Epub 2019 Sep 29. Review.

PMID:
31544557
6.

Corrigendum to "Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system" [Biochem. Pharmacol. 161 (2019) 37-51].

Salaga M, Binienda A, Piscitelli F, Mokrowiecka A, Cygankiewicz AI, Verde R, Malecka-Panas E, Kordek R, Krajewska WM, Di Marzo V, Fichna J.

Biochem Pharmacol. 2019 Nov;169:113636. doi: 10.1016/j.bcp.2019.113636. Epub 2019 Sep 14. No abstract available.

PMID:
31526940
7.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2019 Nov 5;862:172656. doi: 10.1016/j.ejphar.2019.172656. Epub 2019 Sep 10. No abstract available.

PMID:
31519354
8.

Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial.

Tarasiuk A, Milad M, Ahmed ST, Majewski M, Wallner G, Fichna J, Bashashati M, Sarosiek J.

J Gastrointestin Liver Dis. 2019 Sep 1;28(3):263-264. doi: 10.15403/jgld-421.

9.
10.

Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis.

Krajewska JB, Pietruszka P, Tomczyk D, Chen C, Owczarek A, Karolewicz B, Czapor-Irzabek H, Gorniak A, Fichna J.

J Physiol Pharmacol. 2019 Apr;70(2). doi: 10.26402/jpp.2019.2.10. Epub 2019 Aug 20.

11.

Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen.

Mosińska P, Tarasiuk A, Fabisiak A, Krajewska J, Niewinna K, Bartoszek A, Binienda A, Sałaga M, Fichna J.

Pharmacol Rep. 2019 Oct;71(5):899-908. doi: 10.1016/j.pharep.2019.07.010. Epub 2019 Jul 29.

12.

ANO5 mutations in the Polish limb girdle muscular dystrophy patients: Effects on the protein structure.

Jarmula A, Łusakowska A, Fichna JP, Topolewska M, Macias A, Johnson K, Töpf A, Straub V, Rosiak E, Szczepaniak K, Dunin-Horkawicz S, Maruszak A, Kaminska AM, Redowicz MJ.

Sci Rep. 2019 Aug 8;9(1):11533. doi: 10.1038/s41598-019-47849-3.

13.

Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Zatorski H, Sałaga M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2019 Nov;392(11):1321-1330. doi: 10.1007/s00210-019-01698-z. Epub 2019 Jul 29. Review.

PMID:
31359088
14.

1-Substituted sialorphin analogues-synthesis, molecular modelling and in vitro effect on enkephalins degradation by NEP.

Sobocińska M, Giełdoń A, Fichna J, Kamysz E.

Amino Acids. 2019 Aug;51(8):1201-1207. doi: 10.1007/s00726-019-02760-z. Epub 2019 Jul 13.

PMID:
31302778
15.

Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors.

Jacenik D, Cygankiewicz AI, Mokrowiecka A, Małecka-Panas E, Fichna J, Krajewska WM.

Int J Mol Sci. 2019 Jun 28;20(13). pii: E3175. doi: 10.3390/ijms20133175.

17.

Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies.

Mosińska P, Martín-Ruiz M, González A, López-Miranda V, Herradón E, Uranga JA, Vera G, Sánchez-Yáñez A, Martín-Fontelles MI, Fichna J, Abalo R.

Neurogastroenterol Motil. 2019 Sep;31(9):e13651. doi: 10.1111/nmo.13651. Epub 2019 May 30.

PMID:
31145538
18.

Effectiveness and therapeutic value of phytochemicals in acute pancreatitis: A review.

Tarasiuk A, Fichna J.

Pancreatology. 2019 Jun;19(4):481-487. doi: 10.1016/j.pan.2019.04.010. Epub 2019 May 3. Review.

PMID:
31079933
19.

G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease.

Jacenik D, Zielińska M, Mokrowiecka A, Michlewska S, Małecka-Panas E, Kordek R, Fichna J, Krajewska WM.

Sci Rep. 2019 May 1;9(1):6749. doi: 10.1038/s41598-019-43233-3.

20.

The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome.

Szymaszkiewicz A, Malkiewicz A, Storr M, Fichna J, Zielinska M.

J Physiol Pharmacol. 2019 Feb;70(1). doi: 10.26402/jpp.2019.1.01. Epub 2019 Apr 20. Review.

21.

Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus.

Fabisiak A, Bartoszek A, Kardas G, Fabisiak N, Fichna J.

Peptides. 2019 May;115:27-31. doi: 10.1016/j.peptides.2019.02.007. Epub 2019 Mar 1. Review.

PMID:
30831146
22.

High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury.

Zatorski H, Salaga M, Zielińska M, Wasilewski A, Misicka A, Sacharczuk M, Fichna J.

Pharmacol Rep. 2019 Apr;71(2):218-224. doi: 10.1016/j.pharep.2018.10.011. Epub 2018 Oct 25.

PMID:
30785059
23.

High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice.

Zielinska M, Szymaszkiewicz A, Salaga M, Zatorski H, Wlodarczyk J, Jacenik D, Kordek R, Krajewska WM, Misicka A, Fichna J, Sacharczuk M.

J Physiol Pharmacol. 2018 Oct;69(5). doi: 10.26402/jpp.2018.5.11. Epub 2019 Jan 21.

24.

Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system.

Salaga M, Binienda A, Piscitelli F, Mokrowiecka A, Cygankiewicz AI, Verde R, Malecka-Panas E, Kordek R, Krajewska WM, Di Marzo V, Fichna J.

Biochem Pharmacol. 2019 Mar;161:37-51. doi: 10.1016/j.bcp.2019.01.001. Epub 2019 Jan 3. Erratum in: Biochem Pharmacol. 2019 Nov;169:113636.

PMID:
30611738
25.

Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain.

Zielińska A, Sałaga M, Włodarczyk M, Fichna J.

Int J Colorectal Dis. 2019 Feb;34(2):217-227. doi: 10.1007/s00384-018-3218-0. Epub 2018 Dec 19. Review.

26.

Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.

Szymaszkiewicz A, Storr M, Fichna J, Zielinska M.

Neurogastroenterol Motil. 2019 Apr;31(4):e13526. doi: 10.1111/nmo.13526. Epub 2018 Dec 14. Review.

PMID:
30549162
27.

The role of adipose tissue in the pathogenesis of Crohn's disease.

Zielińska A, Siwiński P, Sobolewska-Włodarczyk A, Wiśniewska-Jarosińska M, Fichna J, Włodarczyk M.

Pharmacol Rep. 2019 Feb;71(1):105-111. doi: 10.1016/j.pharep.2018.09.011. Epub 2018 Sep 28. Review.

PMID:
30513401
28.

One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?

Krajewska JB, Fichna J, Mosińska P.

Crit Rev Oncol Hematol. 2018 Dec;132:1-8. doi: 10.1016/j.critrevonc.2018.09.006. Epub 2018 Sep 15. Review.

PMID:
30447913
29.

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron.

Martín-Ruíz M, Uranga JA, Mosinska P, Fichna J, Nurgali K, Martín-Fontelles MI, Abalo R.

Neurogastroenterol Motil. 2019 Mar;31(3):e13499. doi: 10.1111/nmo.13499. Epub 2018 Nov 6.

PMID:
30402956
30.

Enkephalin degradation in serum of patients with inflammatory bowel diseases.

Wilenska B, Tymecka D, Włodarczyk M, Sobolewska-Włodarczyk A, Wiśniewska-Jarosińska M, Dyniewicz J, Somogyi Á, Fichna J, Misicka A.

Pharmacol Rep. 2019 Feb;71(1):42-47. doi: 10.1016/j.pharep.2018.08.001. Epub 2018 Aug 2.

PMID:
30391790
31.

Young GI angle: My biggest (career) mistake.

Fichna J, Vergnolle N, Rooman I.

United European Gastroenterol J. 2018 Oct;6(8):1278-1279. doi: 10.1177/2050640618803045. Epub 2018 Sep 30. No abstract available.

32.

Sleep disturbance and disease activity in adult patients with inflammatory bowel diseases.

Sobolewska-Wlodarczyk A, Wlodarczyk M, Banasik J, Gasiorowska A, Wisniewska-Jarosinska M, Fichna J.

J Physiol Pharmacol. 2018 Jun;69(3). doi: 10.26402/jpp.2018.3.09. Epub 2018 Sep 28.

33.

Myofibrillar myopathy in the genomic context.

Fichna JP, Maruszak A, Żekanowski C.

J Appl Genet. 2018 Nov;59(4):431-439. doi: 10.1007/s13353-018-0463-4. Epub 2018 Sep 10. Review.

PMID:
30203143
34.

Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis.

Salaga M, Binienda A, Draczkowski P, Kosson P, Kordek R, Jozwiak K, Fichna J.

Peptides. 2018 Oct;108:34-45. doi: 10.1016/j.peptides.2018.08.011. Epub 2018 Sep 1.

PMID:
30179653
35.

New Trends in Liposome-based Drug Delivery in Colorectal Cancer.

Krajewska JB, Bartoszek A, Fichna J.

Mini Rev Med Chem. 2019;19(1):3-11. doi: 10.2174/1389557518666180903150928. Review.

PMID:
30179131
36.

Diagnostic value of chemerin in lower gastrointestinal diseases-a review.

Sochal M, Mosińska P, Fichna J.

Peptides. 2018 Oct;108:19-24. doi: 10.1016/j.peptides.2018.08.012. Epub 2018 Aug 27. Review.

PMID:
30165089
37.

Pharmacological and dietary factors in prevention of colorectal cancer.

Waluga M, Zorniak M, Fichna J, Kukla M, Hartleb M.

J Physiol Pharmacol. 2018 Jun;69(3). doi: 10.26402/jpp.2018.3.02. Epub 2018 Aug 22. Review.

38.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17. Erratum in: Eur J Pharmacol. 2019 Nov 5;862:172656.

PMID:
30121173
39.

Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.

Włodarczyk M, Włodarczyk J, Siwiński P, Sobolewska-Włodarczyk A, Fichna J.

Curr Drug Targets. 2018;19(15):1731-1737. doi: 10.2174/1389450119666180803122744. Review.

PMID:
30073926
40.

The effect of long-term melatonin supplementation on psychosomatic disorders in postmenopausal women.

Chojnacki C, Kaczka A, Gasiorowska A, Fichna J, Chojnacki J, Brzozowski T.

J Physiol Pharmacol. 2018 Apr;69(2). doi: 10.26402/jpp.2018.2.15. Epub 2018 Jul 23.

41.

Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders.

Tarasiuk A, Mosińska P, Fichna J.

Chin Med. 2018 Jul 18;13:39. doi: 10.1186/s13020-018-0197-6. eCollection 2018. Review.

42.

Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients.

Fichna JP, Macias A, Piechota M, Korostyński M, Potulska-Chromik A, Redowicz MJ, Zekanowski C.

Hum Genomics. 2018 Jul 3;12(1):34. doi: 10.1186/s40246-018-0167-1.

43.

Chronic abdominal pain in irritable bowel syndrome - current and future therapies.

Zielińska A, Sałaga M, Włodarczyk M, Fichna J.

Expert Rev Clin Pharmacol. 2018 Jul;11(7):729-739. doi: 10.1080/17512433.2018.1494571. Epub 2018 Jul 9. Review.

PMID:
29957084
44.

Inflammation-associated changes in DOR expression and function in the mouse colon.

DiCello JJ, Saito A, Rajasekhar P, Eriksson EM, McQuade RM, Nowell CJ, Sebastian BW, Fichna J, Veldhuis NA, Canals M, Bunnett NW, Carbone SE, Poole DP.

Am J Physiol Gastrointest Liver Physiol. 2018 Oct 1;315(4):G544-G559. doi: 10.1152/ajpgi.00025.2018. Epub 2018 Jun 21.

45.

Bile acids and FXR in functional gastrointestinal disorders.

Mosińska P, Szczepaniak A, Fichna J.

Dig Liver Dis. 2018 Aug;50(8):795-803. doi: 10.1016/j.dld.2018.05.016. Epub 2018 May 30. Review.

PMID:
29908754
46.

Alanine scan of sialorphin and its hybrids with opiorphin: synthesis, molecular modelling and effect on enkephalins degradation.

Sobocińska M, Giełdoń A, Fichna J, Kamysz E.

Amino Acids. 2018 Aug;50(8):1083-1088. doi: 10.1007/s00726-018-2585-8. Epub 2018 May 12.

47.
48.

Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2.

Piekielna-Ciesielska J, Mollica A, Pieretti S, Fichna J, Szymaszkiewicz A, Zielińska M, Kordek R, Janecka A.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):560-566. doi: 10.1080/14756366.2018.1441839.

49.

Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension-proof-of-concept.

Fabisiak A, Sobocińska M, Kamysz E, Fichna J, Zielińska M.

Chem Biol Drug Des. 2018 Jul;92(1):1387-1392. doi: 10.1111/cbdd.13186. Epub 2018 Mar 30.

PMID:
29495100
50.

Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease.

Wezyk M, Szybinska A, Wojsiat J, Szczerba M, Day K, Ronnholm H, Kele M, Berdynski M, Peplonska B, Fichna JP, Ilkowski J, Styczynska M, Barczak A, Zboch M, Filipek-Gliszczynska A, Bojakowski K, Skrzypczak M, Ginalski K, Kabza M, Makalowska I, Barcikowska-Kotowicz M, Wojda U, Falk A, Zekanowski C.

J Alzheimers Dis. 2018;62(1):175-202. doi: 10.3233/JAD-170830.

PMID:
29439343

Supplemental Content

Loading ...
Support Center